The Effect of Saccharomyces Boulardii in Clinical Presentation and Quality of Life Patient With IBS
Launched by FAKULTAS KEDOKTERAN UNIVERSITAS INDONESIA · Jul 5, 2022
Trial Information
Current as of April 30, 2025
Unknown status
Keywords
ClinConnect Summary
This study aims to compare the effectiveness of Saccharomyces Boulardii vs Placebo in patient with Irritable Bowel Syndrome within timeframe of study 28 days and then will be examined the outcome as the improvement quality of life
Gender
ALL
Eligibility criteria
- Inclusion Criterias:
- • 18 years or older
- • diagnosed with IBS based on ROME IV criteria
- • agree to be participant by signing inform consent
- Exclusion Criteria:
- • patient who does not want to sign the inform consent
About Fakultas Kedokteran Universitas Indonesia
Fakultas Kedokteran Universitas Indonesia (FKUI) is a leading medical faculty dedicated to advancing healthcare through innovative research and clinical trials. As a prominent academic institution, FKUI combines rigorous scientific inquiry with a commitment to improving patient outcomes, making significant contributions to medical knowledge and practice. The faculty collaborates closely with healthcare professionals and researchers to conduct high-quality clinical trials, ensuring adherence to ethical standards and regulatory requirements. Through its comprehensive approach to education, research, and clinical excellence, FKUI plays a vital role in shaping the future of medicine in Indonesia and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials